Evidence mapPaperPMID 41704388Full record

ArticleACS medicinal chemistry letters2026

Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.

Giovanni Ferrandi, Greta Bagnolini, Laura Poppi, Mirco Masi, Viola Previtali, Angela Andonaia, Giulia Varignani, Marina Veronesi, Francesca De Franco, Federico Falchi and 4 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giovanni FerrandiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0009-0004-1656-2961
Greta BagnoliniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0001-6237-1235
Laura PoppiComputational and Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.
Mirco MasiComputational and Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.
Viola PrevitaliComputational and Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.
Angela AndonaiaComputational and Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.
Giulia VarignaniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0009-0001-1835-3547
Marina VeronesiStructural Biophysics Facility, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.
Francesca De FrancoTES Pharma S.r.l., I-06073 Corciano, Perugia, Italy.
Federico FalchiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0001-7385-649X
Giuseppina Di StefanoDepartment of Medical and Surgical Sciences, University of Bologna,40126 Bologna, Italy.
Stefania GirottoStructural Biophysics Facility, Istituto Italiano di Tecnologia, 16163 Genoa, Italy.ORCID https://orcid.org/0000-0002-0339-6675
Marinella RobertiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0001-9807-2886
Andrea CavalliDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0002-6370-1176

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic lethality has proven to be a tactical paradigm to design synergistic anticancer drug combinations. In this context, we leveraged BRCA2 and PARP as a synthetic lethal target pair to consolidate the use of small molecule inhibitors of RAD51-BRCA2 protein-protein interaction as inducers of the BRCAness phenotype that sensitizes

Indexed as

pancreatic cancerprotein−protein interaction inhibitorsRAD51-BRCA2small moleculesSynthetic lethality

Identifiers

PMID41704388
PMCPMC12907944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.